People with chronic lymphocytic leukaemia (CLL) stay disease-free and alive for longer when they are treated with a combination of two drugs, according to an interim analysis of a phase 3 clinical trial.
The trial, carried out by researchers at St...
4 years ago
A new specific drug target for primary effusion lymphoma (PEL) – an aggressive type of non-Hodgkin’s lymphoma – has been discovered by a team from the University of North Carolina, USA.
First author Jason Wong explains: “Patients with primary effu...
4 years ago
